Company: CI
Filing Date: 2025-05-02
Form Type: 10-Q
Source: 0001739940-25-000021
Chunk: 177

Company: Cigna Group
Filing Date: 2025-05-02
Form: 10-Q
Item: Part II, Item 4
Chunk 177
---
a Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer) as appropriate to allow timely decisions regarding required disclosure.

Change in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, The Cigna Group's internal control over financial reporting. 

Part II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

The information contained under "Legal and Regulatory Matters" in Note 16 to the Consolidated Financial Statements is incorporated herein by reference.

Item 1A. RISK FACTORS

For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024.

43

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table provides information about The Cigna Group share repurchase activity for the quarter ended March 31, 2025:PeriodTotal # of shares purchased (1)Average price paid per share (1)Total # of shares purchased as part ofpublicly announced program (2)Approximate dollar value of sharesthat may yet be purchased as partof publicly announced program (3) (in millions)January 1-31, 2025187,323 $297.41 186,390 $10,234 February 1-28, 20253,534,073 $300.54 3,198,158 $9,283 March 1-31, 20251,606,082 $317.77 1,591,107 $8,782 Total5,327,478 $305.62 4,975,655 N/A

(1)Includes shares tendered by employees under the Company's equity compensation plans as follows: 1) payment of taxes on vesting of restricted stock (grants and units) and strategic performance shares and 2) payment of the exercise price and taxes for certain stock options exercised. Employees tendered 933 shares in January, 335,915 shares in February and 14,975 shares in March 2025. 

(2)Additionally